11. Assessment of the telomere length and its effect on the symptomatology of Parkinson's diseaseTina Levstek, Sara Redenšek Trampuž, Maja Trošt, Vita Dolžan, Katarina Trebušak Podkrajšek, 2021, izvirni znanstveni članek Ključne besede: Parkinson's disease, telomere length, levodopa treatment, telomere attrition, dementia Celotno besedilo (datoteka, 737,20 KB) Gradivo ima več datotek! Več... |
12. Metabolic brain pattern in dementia with Lewy bodiesMatej Perovnik, Petra Tomše, Jan Jamšek, Chris Chengke Tang, David Eidelberg, Maja Trošt, 2022, izvirni znanstveni članek Ključne besede: dementia with Lewy bodies, Alzheimer’s disease, biomarker, metabolic brain imaging, FDG PET, network analysis, scaled subprofile model/principal component analysis, SSM/PCA Celotno besedilo (datoteka, 2,27 MB) Gradivo ima več datotek! Več... |
13. Genetic variability of the vitamin D receptor affects susceptibility to Parkinson's disease and dopaminergic treatment adverse eventsSara Redenšek Trampuž, Tilen Kristanc, Tanja Blagus, Maja Trošt, Vita Dolžan, 2022, izvirni znanstveni članek Ključne besede: vitamin D receptor, Parkinson’s disease, biomarker, risk, susceptibility, adverse events, vitamin D, polymorphism Celotno besedilo (datoteka, 279,78 KB) Gradivo ima več datotek! Več... |
14. Investigation of paraoxonase-1 genotype and enzyme-kinetic parameters in the context of cognitive impairment in Parkinson’s diseaseBoštjan Petrič, Sara Redenšek Trampuž, Vita Dolžan, Milica Gregorič Kramberger, Maja Trošt, Nikola Maraković, Marko Goličnik, Aljoša Bavec, 2023, izvirni znanstveni članek Ključne besede: Parkinson disease, cognitive impairment, paraoxonase 1, paraoxonase activity, single-nucleotide polymorphisms, iFIT Celotno besedilo (datoteka, 1,14 MB) Gradivo ima več datotek! Več... |
15. Pharmacogenetic markers of adverse events of dopaminergic treatment in Parkinson's diseaseSara Redenšek, 2019, doktorsko delo/naloga Ključne besede: Parkinson's disease, pharmacogenetics, dopaminergic treatment, adverse events, genetic polymorphisms, personalized medicine, clinical-pharmacogenetic models Celotno besedilo (datoteka, 11,02 MB) |
|
|
|
|
|